OSE Immunotherapeutics has patented a method for producing a ready-to-use peptide emulsion on an industrial scale. This process involves emulsifying a peptide suspension with an adjuvant under low shear conditions, ensuring the integrity of the peptides and compliance with pharmaceutical sterility requirements. GlobalData’s report on OSE Immunotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on OSE Immunotherapeutics, Personalized cancer vaccines was a key innovation area identified from patents. OSE Immunotherapeutics's grant share as of June 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
The patent US11981713B2 describes a ready-to-use emulsion formulated through a specific process that involves emulsifying a suspension of various peptides under low shear conditions. The emulsification occurs at a rotation speed between 100 and 1000 rpm for a duration of 2 to 20 minutes, without exceeding a mixing speed of 7000 rpm. The emulsion contains a combination of multiple peptides, including KVFGSLAFV, YLSGADLNL, and others, and is characterized by a D50 particle size of 10±2 µm. The formulation also includes at least one adjuvant, which is a mixture of hydrocarbon oil and a water-in-oil emulsifier, with specific weight ratios of adjuvant to peptide suspension outlined in the claims.
Additionally, the patent details methods for preparing the peptide suspension, which involves creating three distinct solutions with varying pH levels and combining them to achieve a neutral pH. The emulsion is designed for therapeutic applications, particularly in treating cancer in subjects expressing the HLA-A2 receptor. It can be administered alone or in conjunction with other treatment modalities, including chemotherapy, targeted therapies, radiotherapy, or immunotherapy, with a specific mention of checkpoint inhibitor immunotherapy. The claims also specify the concentration of each peptide in the emulsion, ensuring consistency with the amounts used during preparation.
To know more about GlobalData’s detailed insights on OSE Immunotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
